Changing nature of bacteria causing adult upper and lower respiratory tract infections: Focus on β-lactamase-producing bacteria

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 4, 1998, Pages

  Dal Nogare, Anthony R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MONOBACTAM DERIVATIVE; PENAM DERIVATIVE;

BACTERIAL PNEUMONIA; BRONCHITIS; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0031738261     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. World Health Organization. The world health report 1996: fighting disease, fostering development Geneva: World Health Organization: 1996.
2. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States JAMA 1996;275:189-93.
3. Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6.
4. Doern GV, Brueggemann A, Holley HP Jr, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40 1208-13.
5. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.
6. Gwaltney JM Jr. Acute bronchitis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone: 1995. p. 606-8
7. Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996;275:1672-4.
8. Stoller JK, Aboussouan LS. Chronic obstructive lung diseases, emphysema, chronic bronchitis, bronchiectasis, and cystic fibrosis. In: George RB, editor. Chest medicine. 3rd ed. Baltimore: Williams & Wilkins; 1995. p. 201-46.
9. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108(Suppl).43S-52S.
10. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
11. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a metaanalysis. JAMA 1995;273:957-60.
12. Bartlett JG, Mundy LM Community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
13. Baum SG. Mycoplasma pneumoniae and atypical pneumonia. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 1704-13.
14. Grayston JT. Chlamydia pneumoniae (TWAR). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 1696-701.
15. Thorn D. Lower respiratory tract infection with Chlamydia pneumoniae Arch Fam Med 1994;3:828-32
16. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Respir Crit Care Med 1995;153: 1711-25.
17. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
18. Finegold SM. Lung abscess. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 641-6.
19. Neu HC, The crisis in antibiotic resistance Science 1992;257:1064-73
20. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(6B Suppl):3S-7S.
21. Danziger LH, Pendland SL Bacterial resistance to β-lactam antibiotics. Am J Health Syst Pharm 1995;52(2 Suppl):3S-8S.
22. Papanicolaou GA, Medeiros AA. Ability of ceftibuten to induce the class-I β-lactamases of Enterobacter cloacae, Serratia marcescens, and Enterobacter aerogenes. Diagn Microbiol Infect Dis 1991.14:85-7.
23. Phillips I, Shannon K. Importance of β-lactamase induction. Eur J Clin Microbiol Infect Dis 1993;12(1 Suppl): 19S-26S.
24. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:1067-63.
25. Cullmann W Importance of β-lactamase stability in treating today's respiratory tract infections. Respiration 1993, 60(1 Suppl):10-5.
26. Verghese A, Berk SL. Moraxella (Branhamella) catarrbalis. Infect Dis Clin North Am 1991;5.523-38.
27. Styrt B, Gorbach SL. Recent developments in the understanding of the pathogenesis and treatment of anaerobic infections. N Engl J Med 1989,321:240-6.
28. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess Ann Intern Med 1983;98:466-71.
29. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 247-64
30. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997;24(1 Suppl):19S-45S.
31. Sanders CC, Sanders WE Jr. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin infect Dis 1992;15:824-39.
32. Mayer KM, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 212-25.
33. Schito GC, Pesce A, Debbia EA Stability in the presence of widespread β-lactamases: a prerequisite for the antibacterial activity of β-lactam drugs. Drugs 1994;47(3 Suppl):1-9.
34. Thomson KS, Weber DA, Sanders CC, et al. β-Lactamase production in members of the family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990;34:622-7.
35. Sirot D. Extended-spectrum plasmid-mediated β-lactamases. J Antimicrob Chemother 1995;36(A Suppl):19-34.
36. Medeiros AA. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum β-lactamases have arrived in North America Ann Intern Med 1993;119:428-30.
37. Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
38. Rice LB, Yao JDC, Klimm K, et al. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother 1991;35:1243-4.
39. Brun-Buisson C, Legrand P, Philippon A, et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987;2:302-6.
40. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991;324: 601-12.
41. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991;35:1697-704.
42. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
43. Jones RN. Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Diagn Microbiol Infect Dis 1997;27: 21-8